Serum Levels of Receptor Activator of Nuclear Factor-κβ Ligand, Osteoprotegerin, Interlukin-17 and association with Receptor Activator of Nuclear Factor Kappa B/ Osteoprotegerin Ratio in Patients with Osteoporosis.

An imbalance between the formation and resorption of boneleading to  osteoporosis disease which described as drops level of bone mineralization  that result in bone fracture.The current case control study determined levels of (RANKL),  (OPG) and  IL-17 in serum  and the RANKL/OPG ratio for detection this disease , in addition to detect  IL-17 level in patents serum. Method: fifty  patientswith osteoporosis from both genderwith the age range between (50-88)represented-(group1)and-(group 2) of 40 healthy control personsdetection of these biomarkersdone  by ELISA  test. The OPG/RANKL ratio was also calculated. In addition to detection the role of IL-17 in osteoporosis. RANKLlevelsin patients more than those of   control, the difference was high--significant as P < 0.001, serum levels of OPG were lower in patients group in comparison with control group and the difference was highly significant (P < 0.001).The ratio of RANKL/OPG in patients group was-P<0.001(raised significant)-compared to the that of healthy-subjects. Serum levels of IL-17in patients were raising morethan in control with-(P < 0.001). Conclusions:-Serum-levels of RANKL,-OPG-and RANKL-to-OPG percentage were potentialbiomarkers for-detection-osteoporosis, also, serum IL-17 was significantly elevated in osteoporotic patients when compared to healthy control both in male and female patients with osteoporosis.